Bio Essence Corp (BIOE) stock
BIOEOTCPharmaceutical PreparationsFiscal year ends December 31
$0.42+0.03 (+7.72%)
Close on Oct 19, 2026Market cap $22.70MP/E 10.5Yield –
Bio Essence revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Bio Essence's revenue for the twelve months ending Sep 30, 2026 was $3.03M, up 435.2% year over year. For fiscal 2025 it was $1.90M, up 485.8% from the year before. The highest annual figure on record is $1.90M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.90M | +485.8% |
| FY2024 | Dec 31, 2024 | $323.94K | -41.3% |
| FY2023 | Dec 31, 2023 | $551.51K | -11.3% |
| FY2022 | Dec 31, 2022 | $621.59K | -30.0% |
| FY2021 | Dec 31, 2021 | $887.98K | -7.4% |
| FY2020 | Dec 31, 2020 | $958.70K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $253.02K | +85.0% |
| Q2 FY2026 | Jun 30, 2026 | $794.71K | +206.7% |
| Q1 FY2026 | Mar 31, 2026 | $500.54K | +2155.8% |
| Q4 FY2025 | Dec 31, 2025 | $1.48M | +902.6% |
| Q3 FY2025 | Sep 30, 2025 | $136.80K | +1.6% |
| Q2 FY2025 | Jun 30, 2025 | $259.12K | +521.5% |
| Q1 FY2025 | Mar 31, 2025 | $22.19K | -85.7% |
| Q4 FY2024 | Dec 31, 2024 | $147.56K | -43.2% |
| Q3 FY2024 | Sep 30, 2024 | $134.69K | -60.5% |
| Q2 FY2024 | Jun 30, 2024 | $41.70K | -79.1% |
| Q3 FY2023 | Sep 30, 2023 | $155.70K | -18.9% |
| Q2 FY2023 | Jun 30, 2023 | $259.57K | -9.9% |
| Q1 FY2023 | Mar 31, 2023 | $341.33K | +11.4% |
| Q4 FY2022 | Dec 31, 2022 | $199.16K | -6.5% |
| Q3 FY2022 | Sep 30, 2022 | $192.05K | -15.4% |
| Q2 FY2022 | Jun 30, 2022 | $288.14K | +22.1% |
| Q1 FY2022 | Mar 31, 2022 | $306.41K | +44.5% |
| Q4 FY2021 | Dec 31, 2021 | $213.04K | -2.7% |
| Q3 FY2021 | Sep 30, 2021 | $226.99K | -0.6% |
| Q2 FY2021 | Jun 30, 2021 | $235.93K | +15.0% |
| Q1 FY2021 | Mar 31, 2021 | $212.03K | -30.8% |
| Q4 FY2020 | Dec 31, 2020 | $218.93K | – |
| Q3 FY2020 | Sep 30, 2020 | $228.33K | – |
| Q2 FY2020 | Jun 30, 2020 | $205.09K | – |
| Q1 FY2020 | Mar 31, 2020 | $306.35K | – |
See a number that looks wrong?